Alnylam Q4 product rev $451M (+30%); FY rev $1.65B (+33%); vutrisiran sNDA PDUFA Mar 23

ALNYLAM PHARMACEUTICALS, INC.

2024-FY EPS reported -$2.18 revenue$2,248,243,000

Q4 2024 global net product revenues $451M (+30% vs Q4 2023); full year $1,646M (+33%).
Q4 total revenues $593.2M; net loss $83.8M improved from $137.9M loss in Q4 2023.
FDA accepted sNDA for vutrisiran in ATTR cardiomyopathy; PDUFA target date March 23, 2025.
Non-GAAP net income of $8.0M in Q4 vs loss of $96.6M in prior year.
Company reiterates 2025 product sales and profitability guidance; R&D Day Feb 25, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.